Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). We show 22 historical shares outstanding datapoints in our DYN shares outstanding history coverage, used to compute DYN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DYN market cap history over the course of time is important for investors
interested in comparing DYN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DYN versus a peer is one thing; comparing
DYN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DYN can fluctuate over the course of history.
With this page we aim to empower investors researching DYN by allowing them to research the DYN market cap history. |
Free DYN Email Alerts:
Video: The Importance of Market Cap
